Furthermore, to evaluate whether KIF23 could act as an independent prognostic biomarker for glioma patients, we performed a stepwise, multivariate Cox regression analysis incorporating KIF23 expression, KPS score, age, tumor grade and IDH1 mutation status. This evidence concerns the gene IDH1 and central nervous system cancer.